180 related articles for article (PubMed ID: 11193895)
1. Pharmacokinetics of orally administered camptothecins.
Gupta E; Vyas V; Ahmed F; Sinko P; Cook T; Rubin E
Ann N Y Acad Sci; 2000; 922():195-204. PubMed ID: 11193895
[TBL] [Abstract][Full Text] [Related]
2. In vitro activation of irinotecan to SN-38 by human liver and intestine.
Ahmed F; Vyas V; Cornfield A; Goodin S; Ravikumar TS; Rubin EH; Gupta E
Anticancer Res; 1999; 19(3A):2067-71. PubMed ID: 10470149
[TBL] [Abstract][Full Text] [Related]
3. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
4. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
6. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).
Gupta E; Luo F; Lallo A; Ramanathan S; Vyas V; Rubin E; Sinko P
Anticancer Res; 2000; 20(2A):1013-6. PubMed ID: 10810389
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
8. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
[TBL] [Abstract][Full Text] [Related]
9. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
11. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
Morton CL; Wierdl M; Oliver L; Ma MK; Danks MK; Stewart CF; Eiseman JL; Potter PM
Cancer Res; 2000 Aug; 60(15):4206-10. PubMed ID: 10945631
[TBL] [Abstract][Full Text] [Related]
12. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Bouscarel B; Matsuzaki Y; Ceryak S; Kudoh S; Fromm H
Int J Cancer; 1999 Nov; 83(4):491-6. PubMed ID: 10508485
[TBL] [Abstract][Full Text] [Related]
13. Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Ceryak S; Matsuzaki Y; Kudoh S; Bouscarel B
Biochim Biophys Acta; 2001 Feb; 1525(1-2):125-9. PubMed ID: 11342261
[TBL] [Abstract][Full Text] [Related]
14. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
15. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
16. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
17. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
18. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
[TBL] [Abstract][Full Text] [Related]
19. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
20. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs.
Sha X; Fang X
Int J Pharm; 2004 Mar; 272(1-2):161-71. PubMed ID: 15019079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
